Edition:
United Kingdom

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

12.69USD
16 Nov 2018
Change (% chg)

$-0.04 (-0.31%)
Prev Close
$12.73
Open
$12.59
Day's High
$12.83
Day's Low
$12.33
Volume
2,485,277
Avg. Vol
1,325,275
52-wk High
$18.50
52-wk Low
$5.28

Latest Key Developments (Source: Significant Developments)

Endo International Says Timing Of Launch For Cellulite Treatment CCH Will Be Second Half Of 2020
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Endo International PLC ::SAYS EXPECTS TO SUBMIT MARKETING APPLICATION FOR CELLULITE TREATMENT CCH IN SECOND HALF OF 2019 - CONF. CALL.SAYS TIMING OF LAUNCH FOR CELLULITE TREATMENT CCH WILL BE SECOND HALF OF 2020- CONF. CALL.  Full Article

Endo International Q3 Revenues Of $745 Million
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Endo International PLC ::ENDO INTERNATIONAL PLC Q3 REVENUES OF $745 MILLION VERSUS $787 MILLION.ENDO INTERNATIONAL PLC QTRLY REPORTED DILUTED LOSS PER SHARE FROM CONTINUING OPERATIONS OF $0.65.ENDO INTERNATIONAL PLC QTRLY ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS OF $0.71.ENDO INTERNATIONAL PLC SEES FY 2018 TOTAL REVENUES BETWEEN $2.87 BILLION AND $2.92 BILLION.  Full Article

Endo Q3 Adjusted EPS $0.71 From Continuing Operations
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Endo International PLC ::ENDO REPORTS THIRD-QUARTER 2018 FINANCIAL RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.71 FROM CONTINUING OPERATIONS.Q3 GAAP LOSS PER SHARE $0.65 FROM CONTINUING OPERATIONS.Q3 REVENUE $745 MILLION VERSUS I/B/E/S VIEW $694.9 MILLION.Q3 EARNINGS PER SHARE VIEW $0.59 -- THOMSON REUTERS I/B/E/S.RAISES 2018 FINANCIAL GUIDANCE.NOW SEES FY 2018 TOTAL REVENUE $2.87 BILLION TO $2.92 BILLION; ADJUSTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS BETWEEN $2.65 AND $2.75.FY2018 EARNINGS PER SHARE VIEW $2.60, REVENUE VIEW $2.81 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Endo Announces Positive Results From Phase 3 Studies Of Collagenase Clostridium Histolyticum
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Endo International PLC ::ENDO ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDIES OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (CCH) IN PATIENTS WITH CELLULITE.ENDO INTERNATIONAL PLC - CCH WAS WELL-TOLERATED IN ACTIVELY-TREATED SUBJECTS.ENDO INTERNATIONAL - BOTH RELEASE-1 AND RELEASE-2 STUDIES DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT RESULTS ON EFFICACY ENDPOINTS.ENDO INTERNATIONAL PLC - ANNOUNCED POSITIVE RESULTS TODAY FROM TWO IDENTICAL PHASE 3 RELEASE* STUDIES OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM.  Full Article

Par Pharm Inc Wins FDA's Tentative Approval For Topiramate
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Endo International PLC ::PAR PHARM INC WINS FDA'S TENTATIVE APPROVAL FOR TOPIRAMATE - FDA WEBSITE.  Full Article

Endo Agrees To Additional Stay In Litigation Case Against U.S. FDA
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Endo International PLC ::ENDO AGREES TO ADDITIONAL STAY OF FDA LITIGATION FOLLOWING FDA'S COMMITMENT TO USE BEST EFFORTS TO FINALIZE VASOPRESSIN CLINICAL NEED DETERMINATION BY YEAR END.ENDO INTERNATIONAL PLC - AGREED TO AN ADDITIONAL STAY OF ITS LITIGATION AGAINST U.S. FDA UNTIL DECEMBER 31, 2018.ENDO INTERNATIONAL PLC - ENDO AGREED TO PROPOSED STAY AND PARTIES JOINTLY MOVED COURT FOR APPROVAL ON SEPT 21, 2018.ENDO INTERNATIONAL SAYS MOTION WAS UNOPPOSED BY INTERVENOR OUTSOURCING FACILITY.ENDO INTERNATIONAL - IF COURT APPROVES PROPOSED STAY CO'S MOTION FOR PRELIM INJUNCTION TO BE HELD IN ABEYANCE.ENDO INTERNATIONAL PLC - REITERATES PRIOR STATEMENT THAT BULK COMPOUNDING OF VASOPRESSIN BY OUTSOURCING FACILITIES IS "INAPPROPRIATE".ENDO INTERNATIONAL - HEARING ON MOTION FOR PRELIM INJUNCTION CURRENTLY SCHEDULED FOR OCTOBER 3, 2018 WILL BE TAKEN OFF CALENDAR.  Full Article

Endo Lifts Temporary Stay Of FDA Litigation After Launch Of Bulk-Compounded Vasopressin
Wednesday, 15 Aug 2018 

Aug 15 (Reuters) - Endo International PLC ::ENDO LIFTS TEMPORARY STAY OF FDA LITIGATION FOLLOWING THE LAUNCH OF A BULK-COMPOUNDED VASOPRESSIN PRODUCT BY A SECTION 503B OUTSOURCING FACILITY.ENDO INTERNATIONAL PLC - LITIGATION ALSO SEEKS IMMEDIATE REMOVAL OF VASOPRESSIN FROM FDA'S CATEGORY 1 NOMINATIONS LIST.  Full Article

Nevakar And Endo Enter Into Exclusive Licensing Agreement
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Endo International PLC ::NEVAKAR AND ENDO ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR MULTIPLE 505(B)(2) INJECTABLE PRODUCTS.NEVAKAR - ENTERED LICENSING AGREEMENT WITH ENDO INTERNATIONAL'S UNIT FOR DEVELOPMENT OF DIFFERENTIATED, STERILE INJECTABLE PRODUCTS IN U.S. & CANADA.NEVAKAR - PURSUANT TO AGREEMENT, CO TO DEVELOP & SEEK U.S. FDA APPROVAL FOR PRODUCTS TO BE DEVELOPED UNDER AGREEMENT WITH ENDO'S UNIT.NEVAKAR - ENDO'S PAR PHARMACEUTICAL STERILE PRODUCTS DIVISION TO LAUNCH, DISTRIBUTE PRODUCTS DEVELOPED UNDER AGREEMENT UPON FDA APPROVAL.  Full Article

Endo Q2 GAAP Loss Per Share $0.23 From Continuing Operations
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Endo International PLC ::ENDO REPORTS SECOND-QUARTER 2018 FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.76 FROM CONTINUING OPERATIONS.Q2 GAAP LOSS PER SHARE $0.23 FROM CONTINUING OPERATIONS.Q2 REVENUE $715 MILLION VERSUS I/B/E/S VIEW $678.3 MILLION.Q2 EARNINGS PER SHARE VIEW $0.54 -- THOMSON REUTERS I/B/E/S.COMPANY RAISES 2018 FINANCIAL GUIDANCE.SEES 2018 TOTAL REVENUES TO BE BETWEEN $2.75 BILLION AND $2.85 BILLION.SEES 2018 ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS TO BE BETWEEN $2.50 AND $2.60.PHASE 3 TRIALS FOR COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (CCH) EXPECTED TO HAVE TOP-LINE RESULTS IN FOURTH-QUARTER 2018.  Full Article

Bioprojet, Endo Announce Agreement For Paladin Labs To Commercialize Pitolisant In Canada
Wednesday, 25 Jul 2018 

July 25 (Reuters) - Endo International PLC ::BIOPROJET AND ENDO JOINTLY ANNOUNCE AGREEMENT FOR PALADIN LABS INC. TO COMMERCIALIZE PITOLISANT IN CANADA.ENDO INTERNATIONAL - PALADIN WILL BE RESPONSIBLE FOR REGISTRATION DISTRIBUTION, SALES, MARKETING, MEDICAL AFFAIRS IN CONNECTION WITH PITOLISANT.ENDO INTERNATIONAL PLC - BIOPROJET WILL BE RESPONSIBLE FOR SUPPLYING PITOLISANT TO PALADIN.  Full Article

Endo targets 2020 for launch of cellulite treatment

Nov 8 Endo International Plc said on Thursday it expects to launch its treatment for cellulite in the second half of 2020, a day after the company announced results from two late-stage trials testing the drug.